Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

US Expansion

12 Dec 2011 07:00

RNS Number : 7450T
Intercede Group PLC
12 December 2011
 



 

 

Intercede Group plc

 

Intercede Continues US Expansion

 

Company Secures E2 Treaty Investor Status

 

 

Leicestershire, England, December 12, 2011 - Intercede Group plc, the developer of the Intercede MyID® Identity and Credential Management System today announces its has been approved as a United States Treaty Investor (E2) by the US Embassy in London.

 

The company is now able to send qualified executives and employees who are UK citizens to work for Intercede MyID Inc., subject only to them meeting the requirements appropriate to E2 status. Intercede MyID Inc is a wholly owned subsidiary of the Intercede Group with offices in Reston, VA.

 

Treaty Investor employees qualify for E-2 work visas. These are non-immigrant visas for nationals of a country with which the United States maintains a treaty of friendship, commerce and navigation who wish to go to the United States to develop and direct the operations of an enterprise in which the Treaty Investor is investing a substantial amount of capital.

 

Richard Parris, Intercede Chairman and Chief Executive said; "I am delighted Intercede has been recognized as an E2 Treaty Investor. This is the result of an extensive application process. We now have the flexibility to more easily outpost key UK staff to our US business in order to accelerate its growth. This will enable Intercede to strengthen its US infrastructure, transfer technology, recruit and train more US staff, extend the Intercede corporate culture to a wider team and provide US opportunities and experiences to our UK staff. I believe this is a key milestone in the corporate development of the Intercede Group and will be instrumental in enabling increased revenues to be generated from the North American market."

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

 

Andrew Walker, Finance Director

 

 

 

FinnCap

Tel. +44 (0)20 7600 1658

Charles Cunningham, Corporate Finance

 

Rose Herbert, Corporate Finance

 

Joanna Weaving, Corporate Broking

 

 

Pelham Bell Pottinger

Tel. +44 (0)20 7861 3112

Archie Berens

 

Clare Gilbey

 

 

 

 

 

 

 

About Intercede:

Intercede is the producer of the MyID Identity and Credential Management System and MyID Management Agent for Microsoft Forefront Identity Manager 2010.

 

Intercede MyID technology is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 14 federal agencies, two million smart cards in support of the US Transportation Worker Identity Credential program (TWIC), four US financial institutions and 340,000 smart corporate identity badges for Boeing, Booz Allen Hamilton and Lockheed Martin. In Europe, Australasia and the Middle East, Intercede MyID is being deployed in support of government identity, financial services, health and corporate employee ID security projects.

 

Intercede MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management.

 

Intercede MyID was the first electronic personalization product to achieve compliance with the US FIPS-201 Personal Identity Verification (PIV) standard and is widely deployed by federal agencies, government contractors and other commercial entities. In particular, it supports the latest standards applicable for all PIV, PIV-Interoperable and PIV-Compatible deployments.

 

It can issue and manage a wide variety of identities and credentials, providing customers with a platform that can meet their needs now and in the future. It is a fully supported commercial off-the-shelf product that can be quickly deployed for thousands or millions of users.

 

For more information contact:

info@intercede.com or visit www.intercede.com or call +44-1455-558111

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUAAARASAUAUA
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.